Skip to content

Evaluation of the effects of Cydonia Oblonga Mill. fruit syrup on reduction of Biochemical complications induced by Herceptin in patients with breast cancer

Evaluation of the effects of Cydonia Oblonga Mill. fruit syrup on reduction of Biochemical complications induced by Trastuzumab (Herceptin) in patients with breast cancer: A randomized double blind clinical trial study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200427047219N2
Enrollment
60
Registered
2020-05-31
Start date
2020-09-05
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer.

Interventions

Intervention group: Patients with breast cancer receiving quince syrup.

Sponsors

Zanjan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: The desire to participate in the study Breast cancer in the early stages of the disease HER2 positive Women over 18 years Life expectancy more than 3 months (with a doctor's diagnosis) A person should at least be able to walk and do their own thing (WHO performance status 0-2)

Exclusion criteria

Exclusion criteria: Suffering from other cancers Thyroid or kidney disorders Get other vitamin or mineral supplements Patients with a body mass index less than 18.5 Lack of willingness to continue participating in the project for any reason

Design outcomes

Primary

MeasureTime frame
Biochemical factors including: ALP,GGT,ALT, AST. Timepoint: At the beginning of the experiment and 3 months after the intervention. Method of measurement: Laboratory kits.

Secondary

MeasureTime frame
Biochemical factors. Timepoint: Start of study (before the start of the intervention) and 3 months later. Method of measurement: Laboratory kits.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza

Zanjan University of Medical Sciences

eskandarimr@zums.ac.ir+98 24 3347 3638

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026